Thirty patients with advanced gastric carcinoma were treated with doxorubicin combined with mitomycin; only four (13%) responded. Myelosuppression was the major toxic effect; there was one toxic death. The overall median survival was 14 weeks (range, 2-42), which is no different from that reported for untreated patients. The combination of doxorubicin and mitomycin alone cannot be recommended for use in patients with advanced gastric carcinoma.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|State||Published - Jan 1 1986|
ASJC Scopus subject areas
- Cancer Research